List of Excipients in Branded Drug ESOMEPRAZOLE STRONTIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Amneal Pharmaceuticals of New York LLC	ESOMEPRAZOLE STRONTIUM	esomeprazole strontium	53746-955	CALCIUM CARBONATE
Amneal Pharmaceuticals of New York LLC	ESOMEPRAZOLE STRONTIUM	esomeprazole strontium	53746-955	FERRIC OXIDE RED
Amneal Pharmaceuticals of New York LLC	ESOMEPRAZOLE STRONTIUM	esomeprazole strontium	53746-955	GELATIN

Esomeprazole Strontium Excipient Strategy and Commercial Opportunities

Last updated: September 2, 2026

Esomeprazole strontium is a delayed-release proton-pump inhibitor whose commercial value depends on controlling acid stability, moisture exposure, salt equivalence, and enteric release. The strongest excipient opportunities are in multiparticulate pellet systems, moisture-barrier coatings, alkaline stabilization, pediatric or sachet presentations, and differentiated formulations that improve dose flexibility. Generic and hybrid-drug pathways remain more practical than a conventional biologic-style lifecycle strategy because the product is a small-molecule proton-pump inhibitor with established reference-product performance.

What is esomeprazole strontium and how does it differ from esomeprazole magnesium?

Esomeprazole strontium is a strontium salt of the S-enantiomer of omeprazole. It is used in delayed-release dosage forms because esomeprazole is acid-labile and must pass through the stomach without substantial degradation.

The salt contains both esomeprazole and strontium. Dose labeling therefore requires strength conversion. The marketed product has been labeled at 24.65 mg and 49.3 mg of esomeprazole strontium, corresponding approximately to 20 mg and 40 mg of esomeprazole, respectively.[1]

Attribute	Esomeprazole strontium	Esomeprazole magnesium
Active pharmaceutical ingredient	Strontium salt of esomeprazole	Magnesium salt of esomeprazole
Common dosage form	Delayed-release capsule	Delayed-release capsule, tablet, suspension
Primary formulation requirement	Protection from gastric acid and moisture	Protection from gastric acid and moisture
Commercial reference	Esomeprazole strontium delayed-release capsules	Nexium and authorized or generic equivalents
Regulatory pathway	Product-specific NDA or 505(b)(2)-type development history	NDA and ANDA pathways
Key differentiation issue	Salt-specific exposure, strontium load, stability	Established generic and OTC competition
Main excipient challenge	Salt stability and enteric-release reproducibility	Conventional PPI pellet or matrix optimization

The strontium component creates a commercial differentiation opportunity but also introduces additional regulatory scrutiny. A sponsor must control the total strontium dose, establish product-specific safety exposure, and avoid excipient systems that increase dissolution variability.

What excipients are most important for esomeprazole strontium?

The formulation normally requires a core, a protective seal coat, an enteric coat, and a capsule shell. Each layer has a distinct function.

Core excipients

The drug may be layered onto inert starter spheres or incorporated into a compacted multiparticulate core. Suitable core materials can include:

• Sugar spheres
• Microcrystalline cellulose
• Mannitol
• Dibasic calcium phosphate, where compatible with the formulation
• Low-substituted hydroxypropyl cellulose
• Crospovidone or croscarmellose sodium for internal disintegration in compacted systems

Sugar spheres are commercially familiar for proton-pump inhibitor pellets, but they can increase moisture sensitivity and introduce a sugar-related product-positioning issue. Microcrystalline cellulose-based cores may provide stronger mechanical integrity and lower friability.

Alkaline stabilizers

Esomeprazole is unstable in acidic and, under some conditions, humid environments. An alkaline microenvironment can improve stability by limiting local acid catalysis. Potential excipient classes include:

• Magnesium oxide
• Magnesium carbonate
• Sodium carbonate
• Sodium bicarbonate
• Calcium carbonate
• Alkaline buffering combinations

The choice must be controlled. Excess alkalinity can affect dissolution, interact with the strontium salt, alter coating adhesion, or produce a release profile that differs from the reference product. A buffer is therefore a formulation variable, not a routine additive.

Seal-coat excipients

A seal coat separates the drug-containing layer from the enteric polymer and reduces migration of water or acidic components. Candidate materials include:

• Hypromellose
• Polyvinyl alcohol
• Polyvinylpyrrolidone
• Low-viscosity hydroxypropyl cellulose
• Talc
• Titanium dioxide, subject to jurisdictional restrictions
• Triethyl citrate as a plasticizer in selected coating systems

The seal coat is a significant development lever. A thin, continuous film can reduce moisture ingress while preserving rapid release after the enteric layer dissolves at higher pH.

Enteric polymers

The enteric layer determines gastric resistance and intestinal release. Common polymer families include:

• Hypromellose phthalate
• Hypromellose acetate succinate
• Methacrylic acid and ethyl acrylate copolymers
• Methacrylic acid and methyl methacrylate copolymers
• Polyvinyl acetate phthalate
• Cellulose acetate phthalate

Methacrylate systems offer broad control over dissolution pH and film flexibility. Hypromellose phthalate is familiar in delayed-release products but may require careful plasticization and moisture control.

Plasticizers and anti-tacking agents

Plasticizers reduce film brittleness and improve coating uniformity. Common choices include:

• Triethyl citrate
• Acetyl tributyl citrate
• Polyethylene glycol
• Propylene glycol

Talc can limit pellet sticking during coating. Excess talc, however, may lower film permeability, affect dissolution, and create process-control challenges.

What is the optimal excipient architecture for a commercial esomeprazole strontium product?

A multiparticulate capsule is the most defensible platform for a broad commercial program. It separates the drug into many enteric-coated units, reducing the impact of local coating defects and supporting reproducible intestinal release.

A representative architecture is:

Layer	Function	Candidate materials
Inert core	Provides surface for drug loading	Sugar sphere or microcrystalline cellulose
Drug layer	Delivers esomeprazole strontium	API with binder and optional alkaline stabilizer
Seal coat	Limits moisture and polymer interaction	Hypromellose or polyvinyl alcohol
Enteric coat	Resists gastric fluid	Hypromellose phthalate or methacrylate copolymer
Anti-tacking layer	Improves processability	Talc, colloidal silica
Capsule shell	Delivers multiparticulates	Hard gelatin or hypromellose capsule

This structure supports multiple strengths through pellet weight rather than a completely different formulation. It also allows the same pellet platform to be adapted to capsules, sachets, sprinkle products, and potentially orally disintegrating presentations.

What excipient patents could protect esomeprazole strontium formulations?

The highest-value patent claims are unlikely to cover the basic use of a conventional enteric polymer. Broad claims to standard PPI pellets are vulnerable to prior art. Stronger protection can arise from a defined combination of composition, process, and performance limits.

Formulation patent opportunities

Potential claim categories include:

1. A specific esomeprazole strontium-to-alkaline stabilizer ratio.
2. A multilayer pellet with defined seal-coat and enteric-coat weight gains.
3. A low-moisture formulation with specified water activity.
4. An enteric coating that releases above a defined pH while meeting a rapid intestinal dissolution threshold.
5. A pellet population with controlled size distribution and coating thickness.
6. A capsule containing two or more pellet populations with different release profiles.
7. A formulation with reduced strontium dissolution variability.
8. A product that maintains assay and dissolution after accelerated stability storage.
9. A pediatric sprinkle composition that remains stable after mixing with soft food.
10. A capsule or sachet that avoids gelatin-related moisture transfer.

Performance claims should be tied to measurable parameters. Useful parameters include acid-stage dissolution, buffer-stage dissolution, assay after storage, related substances, water activity, pellet friability, and enteric-film weight gain.

Manufacturing-process patent opportunities

Process claims may be stronger than simple ingredient-list claims. Candidate areas include:

• Fluid-bed drug layering at controlled inlet humidity
• Sequential application of alkaline stabilizer and API
• Use of a low-moisture aqueous or nonaqueous coating system
• In-line monitoring of pellet moisture
• Enteric coating under controlled atomization and curing conditions
• Coating methods that reduce agglomeration
• Continuous manufacturing of multiparticulates
• Solvent-reduced coating systems
• Encapsulation under controlled relative humidity

These claims can create barriers even when competitors use the same active ingredient and broadly similar excipients.

What formulation problems must an excipient strategy solve?

Acid degradation

The product must resist gastric fluid. Enteric polymer selection, coat weight, and film integrity are the core controls. The formulation should also limit acidic excipients and avoid water-bearing processes that expose the API to prolonged humidity.

Moisture sensitivity

Moisture can increase degradation and affect capsule performance. Commercial packaging may require high-barrier blistering, desiccant bottles, or both. A moisture-scavenging formulation can reduce packaging cost, but its patentability depends on demonstrable stability improvement.

Strontium-related compatibility

Strontium may interact with inorganic excipients or alter the ionic environment within the drug layer. Compatibility screening should focus on:

• Assay loss
• New degradant formation
• Changes in particle morphology
• Dissolution drift
• Metal-ion interactions
• Changes in enteric-film adhesion

Calcium- or magnesium-containing excipients should not be treated as interchangeable merely because they are common in PPI formulations.

Dose uniformity

Multiparticulate systems require control of pellet loading, segregation, capsule fill weight, and pellet size. The formulation should minimize density differences between coated pellets and uncoated excipient particles.

Enteric-release variability

The product must pass acid resistance and then release rapidly in intestinal buffer. Excessive coating thickness can delay release. Insufficient coating can cause premature drug release and loss of bioequivalence.

What commercial opportunities exist for esomeprazole strontium?

Generic or hybrid delayed-release capsules

The main opportunity is a cost-efficient prescription product using a validated multiparticulate platform. Differentiation can focus on manufacturing efficiency, packaging, dose flexibility, and supply reliability rather than a new mechanism of action.

Pediatric formulations

Pediatric opportunities include:

• Sprinkle capsules
• Sachets
• Granules for suspension
• Low-strength dosage units
• Soft-food administration
• Flavor-masked oral powders

A pediatric product must preserve enteric protection after dispersion. The granules cannot be crushed or dissolved in acidic vehicles that damage the coating.

Hospital and institutional packaging

Unit-dose blister packs, stable room-temperature products, and dosage forms suitable for medication carts can create institutional value. Long-term stability and simplified administration may matter more than novel excipient selection.

Combination products

Potential combinations include esomeprazole with antibiotics for Helicobacter pylori eradication or with agents used in acid-related gastrointestinal disease. Combination development introduces separate regulatory and intellectual-property issues for each active ingredient.

A strontium-based combination product may face a higher safety and labeling burden than a magnesium-based product. The commercial case would need to rest on a specific adherence, dosing, or stability benefit.

OTC or consumer-health positioning

A direct-to-consumer opportunity would require a regulatory strategy distinct from a prescription generic. The sponsor would need to address self-selection, labeling, duration of use, dose strength, and the rationale for using the strontium salt. The established OTC presence of esomeprazole magnesium creates a high competitive barrier.

What is the FDA regulatory status of esomeprazole strontium?

FDA has listed esomeprazole strontium delayed-release capsules as an approved prescription product in 24.65 mg and 49.3 mg strengths, corresponding to 20 mg and 40 mg of esomeprazole, respectively.[1] The product is distinct from esomeprazole magnesium because the salt form changes the active pharmaceutical ingredient description and can affect the regulatory pathway.

The principal regulatory issues are:

Regulatory issue	Commercial implication
Salt-specific product characterization	Requires control of strontium content and API identity
Delayed-release performance	Requires acid resistance and intestinal release testing
Reference-product comparison	Bioequivalence or comparative clinical evidence may be required
Strontium exposure	Requires dose justification and safety assessment
Excipient differences	May require comparative dissolution and stability support
Capsule or granule presentation	May create a separate product-specific development program

FDA guidance for orally administered immediate-release and modified-release products provides the general framework for dissolution and bioequivalence work, but the salt form and delayed-release design determine the specific study requirements.[2]

What patents and exclusivity issues affect commercial entry?

Esomeprazole strontium should be analyzed separately from Nexium and esomeprazole magnesium patent estates. Relevant rights may cover:

• The esomeprazole molecule
• Specific salts
• Delayed-release formulations
• Pellet and coating structures
• Methods for treating GERD and erosive esophagitis
• Pediatric dosing
• Combination therapy
• Manufacturing processes

The commercial risk is usually lower for expired basic compound claims but can remain meaningful for later formulation or method-of-use patents. Paragraph IV challenges may arise where an ANDA applicant seeks approval before expiry of listed patents. A 505(b)(2) applicant may instead address listed patents through certification, labeling carve-outs, or litigation.

Orange Book status

The Orange Book is the controlling source for FDA-listed patents, exclusivity, therapeutic-equivalence evaluations, and discontinued-product status.[3] Esomeprazole strontium requires product-specific review because its listing is separate from esomeprazole magnesium products.

A commercial diligence review should distinguish:

• Patents listed for the strontium product
• Patents listed for esomeprazole magnesium reference products
• Active versus expired patents
• Method-of-use patents subject to labeling carve-outs
• Patent delistings and court outcomes
• Whether the product is currently designated as therapeutically equivalent to a reference product

Which companies are challenging or competing with esomeprazole strontium?

Competition comes from several groups:

1. Generic manufacturers selling esomeprazole magnesium delayed-release capsules.
2. Brand and authorized-generic versions of Nexium.
3. OTC esomeprazole products.
4. Other proton-pump inhibitors, including omeprazole, lansoprazole, pantoprazole, and rabeprazole.
5. H2-receptor antagonists for intermittent or lower-acuity symptoms.
6. Combination products for H. pylori treatment.

Esomeprazole strontium has a limited commercial moat if it competes only on active ingredient and strength. Its stronger positioning would come from a protected delivery platform, a pediatric indication, a differentiated package configuration, or a manufacturing advantage.

How strong is the patent estate for an esomeprazole strontium excipient platform?

A basic formulation using a conventional pellet core, hypromellose seal coat, and methacrylate or phthalate enteric coat would likely face substantial prior-art pressure. Patent strength improves when the formulation demonstrates an unexpected technical result.

Patent concept	Expected defensibility
Generic enteric-coated pellet	Low
Defined alkaline stabilizer ratio	Moderate
Specific multilayer coating sequence	Moderate
Moisture-barrier system with stability data	Moderate to strong
Strontium-specific dissolution control	Stronger if technically demonstrated
Pediatric sprinkle system	Moderate, depending on prior art
Continuous coating process	Moderate to strong
Broad use of standard excipients	Low

The best filing strategy would combine composition claims with process claims and product-by-process performance data. A formulation patent without comparative stability or dissolution evidence may have limited value in litigation.

What generic launch scenarios exist?

Scenario 1: Conventional delayed-release capsule

This is the lowest-cost route and the most exposed to price erosion. Success depends on efficient manufacturing and supply reliability.

Scenario 2: Differentiated multiparticulate platform

A controlled pellet system with improved stability, smaller capsule size, or superior dose flexibility can support a higher-value product, particularly in licensing or hospital channels.

Scenario 3: Pediatric or sprinkle product

This offers more defensible formulation value but requires additional development, administration studies, and labeling work.

Scenario 4: Combination product

This can expand clinical utility but increases development complexity, patent exposure, and manufacturing burden.

Scenario 5: OTC-oriented product

This has the broadest consumer market but faces direct competition from established esomeprazole magnesium products and requires a more extensive regulatory and commercial program.

How does esomeprazole strontium compare with other proton-pump inhibitors?

Product	Main commercial strength	Main competitive weakness
Esomeprazole strontium	Salt-specific formulation and potential differentiated delivery	Limited market familiarity and strontium-related regulatory burden
Esomeprazole magnesium	Strong clinical recognition and broad generic availability	Intense price competition
Omeprazole	Large installed base and low manufacturing cost	Older product with extensive generic competition
Pantoprazole	Institutional and prescription familiarity	Mature generic market
Lansoprazole	Established delayed-release and pediatric experience	Mature competition
Rabeprazole	Differentiated pharmacologic profile	Smaller commercial base

Key Takeaways

• The most attractive excipient platform is a moisture-controlled multiparticulate capsule with a protected drug layer, seal coat, and enteric film.
• Alkaline stabilizers, coating sequence, water activity, and strontium-specific dissolution behavior are the main formulation variables.
• Standard enteric-coated pellets offer limited patent strength unless supported by unexpected stability, release, or manufacturing results.
• Pediatric sprinkle, sachet, and granule products provide the clearest formulation-led commercial expansion opportunities.
• Generic competition from esomeprazole magnesium and other proton-pump inhibitors will constrain pricing.
• The Orange Book, FDA approval records, and current labeling control product-specific patent, exclusivity, and therapeutic-equivalence analysis.
• The strongest intellectual-property strategy combines composition, process, and performance claims.

FAQs About Esomeprazole Strontium Excipients and Commercialization

What is the best enteric polymer for esomeprazole strontium?

A methacrylic acid copolymer or hypromellose phthalate system can be suitable, but selection depends on acid resistance, intestinal release pH, coating process, and compatibility with the strontium salt.

Can esomeprazole strontium be formulated as an orally disintegrating tablet?

Yes, but the drug should generally remain in enteric-coated multiparticulates within the tablet. Direct compression must not fracture the enteric film.

Is magnesium oxide compatible with esomeprazole strontium?

Magnesium oxide may provide an alkaline microenvironment, but compatibility must be demonstrated through assay, degradation, dissolution, and stability testing. It should not be assumed to be interchangeable with other alkaline excipients.

Can esomeprazole strontium be used in a pediatric suspension?

A suspension or granule-for-suspension product is technically possible, but the formulation must preserve enteric protection after reconstitution and during administration.

Does esomeprazole strontium have a biosimilar market?

No. Esomeprazole strontium is a small-molecule salt, not a biologic. Competitive entry is evaluated through small-molecule drug approval pathways rather than biosimilar regulation.

References

1. U.S. Food and Drug Administration. (n.d.). Esomeprazole strontium delayed-release capsules prescribing information. Drugs@FDA and DailyMed.

2. U.S. Food and Drug Administration. (2000). Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.

4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Dissolution and dosage-form standards.

5. European Medicines Agency. (n.d.). Esomeprazole: Product information and quality considerations for gastro-resistant dosage forms.